home / stock / invvy / invvy news

INVVY News and Press, Indivior PLC ADR From 04/09/19

Stock Information
Company Name: Indivior PLC ADR
Stock Symbol: INVVY
Market: OTC
Website: indivior.com
Menu
INVVY INVVY Quote INVVY Short INVVY News INVVY Articles INVVY Message Board
Get INVVY Alerts

News, Short Squeeze, Breakout and More Instantly...
INVVY - Statement of Indivior on Grand Jury Indictment

SLOUGH, United Kingdom and RICHMOND, Va. , April 9, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) issued the following statement today in response to an indictment returned by a federal grand jury in the Western District of Virginia : "We are extremely disappointed in thi...
INVVY - Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference

SLOUGH, England and RICHMOND, Va., April 6, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two new studies: the first provides insights into dosing of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII) fo...

INVVY - Indivior's Sublocade shows sustained benefit in opioid use disorder study

Results from a Phase 3 clinical trial, RECOVER, evaluating Indivior PLC's ( OTCPK:INVVY ) SUBLOCADE (buprenorphine extended-release), administered via subcutaneous injection once per month, in patients with severe opioid use disorder (OUD) showed a sustained treatment benefit. The data we...

INVVY - Indivior's RECOVER(TM) Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later

SLOUGH, England and RICHMOND, Va. , April 5, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII) for the t...
INVVY - The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)

SLOUGH, England and RICHMOND, Va. , March 7, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status and healthcar...

INVVY - Indivior Announces Launch of PERSERIS(TM) (risperidone) for the Treatment of Schizophrenia in Adults

SLOUGH, England and RICHMOND, Va. , Feb. 27, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the launch of once-monthly PERSERIS ™ (risperidone) for extended-release injectable suspension in the United States . PERSERIS is approved by the U.S. Food and Dru...

INVVY - Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic

SLOUGH, England and RICHMOND, Va. , Feb. 20, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The a...
INVVY - The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)

SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 19, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that data from its pivotal phase 3 clinical trial evaluating the efficacy, safety and tolerability of SUBLOCADE TM (buprenorphine extended-release) injection for subcu...

INVVY - Indivior PLC (INVVY) CEO Shaun Thaxter on Q4 2018 Results - Earnings Call Transcript

Indivior PLC (INVVY) Q4 2018 Earnings Conference Call February 14, 2019 06:30 AM ET Company Participants Shaun Thaxter - CEO Mark Crossley - CFO Javier Rodriguez - Chief Legal Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Graham Parr...

INVVY - INDIVIOR PLC ADR 2018 Q4 - Results - Earnings Call Slides

The following slide deck was published by INDIVIOR PLC ADR in conjunction with their 2018 Q4 earnings Read more ...

Previous 10 Next 10